🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Microsatellite Stable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  2. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer, Metastatic

    phase 2 small molecule active

    1 trial

  3. Exercise Training

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 other completed

    1 trial

  4. Exicorilant

    CORCEPT THERAPEUTICS INC

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  5. Experimental

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Cancer (LARC)

    phase 2 small molecule active

    1 trial

  6. FHD-286

    Foghorn Therapeutics

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. FOG-001

    Parabilis Medicines

    Cancer

    phase 2 small molecule active

    1 trial

  8. FOLFIRI

    Eisai Co.,

    Colon Cancer

    phase 2 small molecule terminated

    1 trial

  9. FOLFIRI regimen

    Cardiff Oncology

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  10. FOLFOX/FOLFIRI

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unresectable or Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  11. FOLFOXIRI

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colon Cancer

    phase 2 small molecule active

    1 trial

  12. FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracil Accord 50 mg/ml Injektions-/ Infusionslösung, Fluorouracile AHCL 50 mg/ml, Soluzione per iniezione o infusione, SOTORASIB, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, FLUOROURACILE ACCORD 50 mg/ml, solutio

    CERO THERAPEUTICS HOLDINGS, INC.

    colorectal cancer

    phase 2 small molecule active

    1 trial

  13. FOLINIC ACID, FLUOROURACIL, BEVACIZUMAB, Telisotuzumab adizutecan, FOLINIC ACID, PANITUMUMAB, OXALIPLATIN

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  14. FP-1039

    Prime Medicine

    Endometrial Cancers With FGFR2 Mutations

    phase 2 small molecule terminated

    1 trial

  15. FRUZAQLA 5 mg hard capsules, FLUOROURACIL, FOLINIC ACID, FLUOROURACIL, IRINOTECAN, OXALIPLATIN, Avastin 25 mg/ml concentrate for solution for infusion., FRUZAQLA 1 mg hard capsules

    CERO THERAPEUTICS HOLDINGS, INC.

    métastatique colorectal cancer

    phase 2 small molecule active

    1 trial

  16. FRUZAQLA 5 mg hard capsules, Tevimbra 100 mg concentrate for solution for infusion, FRUZAQLA 1 mg hard capsules, Lonsurf 15 mg/6.14 mg film-coated tablets, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Metastatic Colorectal Cancer without liver metastases

    phase 2 small molecule active

    1 trial

  17. FRα peptide plus Adjuvant (GM-CSF)

    Marker Therapeutics

    Platinum Sensitive Ovarian Cancer

    phase 2 mab terminated

    1 trial

  18. FULVESTRANT, M1774 50mg, M1774 30mg

    The George Institute

    advanced breast cancer

    phase 2 small molecule active

    1 trial

  19. FULVESTRANT, camizestrant, camizestrant

    AstraZeneca AB

    Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  20. FWD1802

    Forward Pharmaceuticals Co.,

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  21. Famitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule on hold

    1 trial

  22. Faslodex 250 mg solution for injection., PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB

    Ningbo Cancer Hospital

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

  23. Fentanyl

    Teva Pharma GmbH

    Cancer

    phase 2 small molecule completed

    1 trial

  24. Fentanyl Buccal Tablet

    Teva Pharma GmbH

    Advanced Cancers

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources